Reaching the 2010 Measles Mortality Reduction Goal-can SEARO get there? Meeting of the Partners for Measles Advocacy Washington DC, 23-24 September 2008.

Slides:



Advertisements
Similar presentations
Global Measles and Rubella Strategic Plan
Advertisements

1 |1 | Countries using and planning to introduce IPV July 2014 status report This slide deck provides a summary per country on the status of planning for.
1 June 2011 Measles update- India Dr. Satish Kumar Gupta Health Specialist UNICEF- India 13 th September 2011.
1 Dr. Azhar Abid Raza Washington Sept 2011 Measles elimination in Pakistan.
1 |1 | Countries using and planning to introduce IPV.
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
The Cape Verde experience with rubella outbreak & lessons from introducing rubella vaccines MoH Cape Verde ARCI meeting Dar es Salaam, Tanzania Dec 2012.
A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
Vaccine in National Immunization Programme Update March 2015.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
World Health Organization
1 |1 | Countries using and planning to introduce IPV.
Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Measles containing vaccine (MCV1) coverage in the WHO European Region.
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.
World Health Organization
Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.
1 1 Measles elimination and rubella control in the SEA Region- a brief Update 12 th Annual Meeting of the Measles Rubella Initiative (MRI) September,
1 |1 | Countries using and planning to introduce IPV.
Update on the Implementation of Measles 2 nd Dose in India Ms. Anuradha Gupta Joint Secretary, Ministry of Health Govt. of India Global Measles and Rubella.
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
MEASLES MORTALITY REDUCTION IN INDIA Status and Future Plans.
Update on Measles Mortality Reduction Activities and Linkages with RI.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV and the global status of bOPV registration Countries using and planning to introduce IPV and the global.
1 1 Bose: SEAR Highlights and Priorities Global Measles & Rubella Management Meeting Geneva, March 2011 Accelerated Measles Control: Highlights and.
1 Progress Towards Global and Regional Immunization Goals Workshop on Prevention and Control of Vaccine Preventable Disease in Displaced Person Temporary.
Global Overview of Measles & Rubella 11 th Annual Meeting The Measles Initiative Washington, DC th September, 2012.
AFR MR TAG Global Measles and Rubella Update 5 th African Regional Measles/Rubella TAG Meeting 2 nd -3 rd June 2015.
The changing vaccination landscape and the sources of vaccination data
1 |1 | Measles pre-elimination and resurgence in the African region Balcha Masresha IVD AFRO Global Measles Management Meeting Geneva March 2011.
WHO and International Panel International Collaborative Effort on Injury Statistics Hyatt Regency, Washington September 7-8, 2006.
India: Transitioning of Polio Network to Support Other Immunization Activities Jeffrey W McFarland, MD Regional Advisor, WHO South-East Asia Regional Office.
Update on Progress toward Measles Situation in EMR September 2008 Dr B. Naouri VPI/DCD/EMRO.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
2015 Measles & Rubella Initiative Annual Partners Meeting, Human & Financial Costs of Measles and Rubella, 15 September 2015, Washington, DC Achieving.
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
Sustaining the gains and reaching milestones on the way towards elimination of measles and rubella 15 September 2015 Dr Peter Strebel, WHO, IVB/EPI.
Vaccine in National Immunization Programme Update April 2016.
Global Measles and Rubella: Highlights, Priorities and Critical Issues
World Health Organization
Global Overview of Measles
Measles disease An acute viral infection spread via respiratory secretions or aerosols Classic manifestations: Maculopapular rash Fever +cough + coryza/conjuctivities.
reporting rate of discarded cases* per 100'000 population**
World Health Organization
Session 1: New Opportunities and New Direction
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
World Health Organization
Countries having introduced HepB vaccine
Countries Using Mening Vaccine in National Immunization Schedule 2011
- Use same categories as for bar chart below Introduced Without GAVI
Onset of most recent case Number of infected districts
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
World Health Organization
World Health Organization
Presentation transcript:

Reaching the 2010 Measles Mortality Reduction Goal-can SEARO get there? Meeting of the Partners for Measles Advocacy Washington DC, September 2008 Dr. Pem Namgyal Regional Adviser, Vaccine Preventable Diseases Immunization and Vaccine Development Department of Family and Community Health, SEARO

Immunization and Vaccine Development, FCH | Regional Strategic Plan Goal By 2010 reduce the number of estimated measles deaths by 90% in comparison to 2000 Specific objectives 1 st dose measles coverage >90%, nationally and >80% coverage in all districts by 2010 Provide a second opportunity for measles immunization by 2010 while achieving >90% coverage Case based measles surveillance within integrated surveillance systems in countries that completed catch- up campaigns Fully investigate all detected/reported measles outbreaks

Immunization and Vaccine Development, FCH | 41 million people were vaccinated in SIAs in 2007 Sources: Mortality estimate WHO/HQ MCV1 coverage: WHO/UNICEF best estimates Estimated measles mortality reduced by 26% between 2000 and 2006

Immunization and Vaccine Development, FCH | Measles 2 nd Opportunity through Routine Immunization Catch-up Campaigns completed Measles 2 nd Opportunity through Catch-up Campaigns Provide MR/MMR vaccine Bhutan, Maldives and Sri Lanka provided MR Follow up campaigns planned : Nepal (2008), Bangladesh (2010) 116 million people have been vaccinated from Provide Measles Vaccine Second Opportunity for Measles Immunization, SEAR, 2008

Immunization and Vaccine Development, FCH | SEAR Measles Lab Network 2008 (July) The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved NIV Pune BJM Ahm IoS Kol Ref lab for genotyping (India) (18) (1)

Immunization and Vaccine Development, FCH | Cases from Serologically Confirmed Suspected Measles Outbreaks Nepal, July Source: Monthly case-based data, Jul 2008

Immunization and Vaccine Development, FCH | Cases from Serologically Confirmed Suspected Measles Outbreaks Bangladesh, July Source: Monthly case-based data, Jul 2008

Immunization and Vaccine Development, FCH | Estimated Measles Mortality, India, % deaths In 10 states ~ 150,000 Deaths

Immunization and Vaccine Development, FCH | Measles: routine coverage and surveillance in India Measles routine coverage in India is low, but showing progressive improvement Surveillance in general is poor; in six southern states WHO SMO network is supporting the state government to carry out measles surveillance Surveillance needs to be established in other states as well, but who is to do it is the current debate

Immunization and Vaccine Development, FCH | Total cases- 678 Total cases Total cases-1132 Andhra PradeshGujarat Tamil Nadu Total cases- 314 Kerala Total cases-1838 West Bengal Total cases Karnataka Serologically confirmed measles outbreaks India: cases by age, 2007 Cases from serologically confirmed measles outbreaks %% %% * data as on 10 th Jul, 2008

Immunization and Vaccine Development, FCH | India Technical Advisory Group for Measles Control (ITAGM) In 2007 GoI formed the India Technical Advisory Group for Measles (ITAGM) comprising national and international experts to guide the government on the future steps for measles mortality reduction in India ITAGM held its 1 st meeting in September 2007 and put up its recommendations to National Technical Advisory Group on Immunization (NTAGI) NTAGI met on 16 June 2008 endorsed ITAGM recommendations

Immunization and Vaccine Development, FCH | ITAGM – State specific strategies Gro up 1 st dose coverage with MCV Strategy 1 Low  Improve RI  One-time catch-up SIA targeting children 9m-10 years*  Repeat SIAs targeting new birth cohorts based on RI coverage and surveillance data 2 Medium  Improve RI  One-time catch-up SIA targeting children 9m-10 years*  Repeat SIAs targeting subsequent birth cohorts and/or introduction of a routine 2nd dose 3 High (>90%)  Introduce a routine 2 nd dose of measles vaccine *Target age range for SIAs will be adjusted based on age distribution of recent cases

Immunization and Vaccine Development, FCH | NTAGI Recommendations for Measles control a) UIP second dose (MR): States with >=80% evaluated MCV1 b) Catch-up measles SIA campaigns (9mo-10 YR): States with <80% evaluated MCV1. c) For UP, decision on catch-up SIA after consultation with State Government. d) CFR studies: in selected high burden states. Draft proposal developed, being reviewed e) Expansion of measles surveillance will be done in UP and Bihar and other states with high mortality due to measles for SIA planning and having a baseline.

Immunization and Vaccine Development, FCH | Recommendations of ITAG and regional priorities Implementation of NTAGI recommendations on accelerating measles mortality reduction in India. –Most importantly, the 10 states of India that account for 90% of measles mortality need to conduct measles catch-up SIAs as soon as possible. Technical sub-group to develop SEAR regional rubella control policy and providing more comprehensive guidance on implementation of measles control and surveillance. All countries that have completed catch-up campaigns should initiate measles case-based surveillance with laboratory confirmation and fully investigation of all detected/reported outbreaks.

Immunization and Vaccine Development, FCH | Can SEA Region Make it? The answer is Yes if we can get India to accelerate the process The problem is neither financial nor technical The most influential partners and from the highest level need to emphasize to the highest authorities in India the importance of India’s achievement to the regional and global ability to achieve the goal for measles mortality reduction

Immunization and Vaccine Development, FCH | THANK YOU